PDCD1 and ovarian cancer: Another study demonstrated that genetically engineered γδ T cells secreting anti-PD-1 antibodies (Lv-PD1-γδ T cells) exhibit enhanced cytotoxicity and therapeutic efficacy against ovarian cancer compared to conventional γδ T cells.